Phase 2 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men and women aged 18 or older but under 45 years old
- People who have plaque psoriasis but do not have psoriatic arthritis (a joint condition related to psoriasis)
- People whose psoriasis is mild, with a disease severity score (called PASI) between 2 and 6
- People who have at least one psoriasis patch on the elbows, knees, or lower back (having patches on other parts of the body as well is fine)
- People whose psoriasis has either been present for less than 6 months, or for more than 2 years
- People who have not used any cream, ointment, or other skin treatment on their psoriasis for at least 2 weeks before joining
- Women who could become pregnant must have been using an effective form of contraception (such as the pill, implant, IUD, condoms, or tubal ligation) for more than one month before joining, and must agree to continue using contraception during the study
- Women who are completely and permanently unable to become pregnant do not need to use contraception or take a pregnancy test
- Women who are not sexually active do not need to use contraception, but must agree to start using it if they become sexually active during the study
- People who are covered by a social security or health insurance system
- People who are willing and able to attend all required study visits
- People who have read and signed a consent form agreeing to take part
Who may not be able to join:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study
- People who have used immune-suppressing medications or steroid treatments (either on the skin or taken internally) in the past 12 weeks
- People with a personal history of skin cancer
- People who have had any cancer within the last 5 years
- People who currently have an active infection
- People with abnormal blood test results (specifically low white blood cells or low platelets), or who test positive for HIV, Hepatitis B, or Hepatitis C at the screening stage
- People who have a history of keloid scarring (a type of raised, overgrown scar tissue)
- People who have had an allergic reaction to local anaesthetics containing xylocaine (lidocaine) and/or adrenaline (epinephrine)
- Minors (under 18), adults under legal guardianship, or people who are not legally free to make their own decisions
- People who are currently taking part in another clinical trial involving a medication that could interfere with this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thierry Passeron, PhD, CHU de Nice, Service de Dermatologie
Phone: +33492036488
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy of bimekizumab versus topical corticosteroids on psoriasis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.